TWI323265B - Antibodies - Google Patents

Antibodies Download PDF

Info

Publication number
TWI323265B
TWI323265B TW092121286A TW92121286A TWI323265B TW I323265 B TWI323265 B TW I323265B TW 092121286 A TW092121286 A TW 092121286A TW 92121286 A TW92121286 A TW 92121286A TW I323265 B TWI323265 B TW I323265B
Authority
TW
Taiwan
Prior art keywords
ser
thr
gly
antibody
val
Prior art date
Application number
TW092121286A
Other languages
English (en)
Chinese (zh)
Other versions
TW200403254A (en
Inventor
Henry Ellis Jonathan
Germaschewski Volker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200403254A publication Critical patent/TW200403254A/zh
Application granted granted Critical
Publication of TWI323265B publication Critical patent/TWI323265B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW092121286A 2002-08-06 2003-08-04 Antibodies TWI323265B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies

Publications (2)

Publication Number Publication Date
TW200403254A TW200403254A (en) 2004-03-01
TWI323265B true TWI323265B (en) 2010-04-11

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092121286A TWI323265B (en) 2002-08-06 2003-08-04 Antibodies

Country Status (23)

Country Link
US (2) US7612183B2 (https=)
EP (1) EP1526868B1 (https=)
JP (1) JP4528121B2 (https=)
KR (1) KR101078459B1 (https=)
CN (1) CN100542607C (https=)
AR (1) AR040778A1 (https=)
AU (1) AU2003255390B2 (https=)
BR (1) BR0312456A (https=)
CA (1) CA2494008C (https=)
CY (1) CY1114919T1 (https=)
DK (1) DK1526868T3 (https=)
ES (1) ES2440652T3 (https=)
IL (1) IL165478A (https=)
IS (1) IS7576A (https=)
MX (1) MXPA05001468A (https=)
MY (1) MY148409A (https=)
NO (1) NO333876B1 (https=)
NZ (1) NZ537123A (https=)
PL (1) PL211014B1 (https=)
PT (1) PT1526868E (https=)
SI (1) SI1526868T1 (https=)
TW (1) TWI323265B (https=)
WO (1) WO2004014953A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2271323A2 (en) 2008-05-06 2011-01-12 Glaxo Group Limited Encapsulation of biologically active agents
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
WO2011085289A1 (en) * 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
NZ605260A (en) * 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
RU2711322C1 (ru) 2013-12-20 2020-01-16 Ф. Хоффманн-Ля Рош Аг Улучшенные способы получения рекомбинантного полипептида
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
BR112018006237A2 (pt) * 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
HU220799B1 (hu) * 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
HUP9900060A3 (en) 1995-04-19 2001-08-28 Acorda Therapeutics New York Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
WO1997001352A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
AU6858596A (en) 1995-08-25 1997-03-19 Johns Hopkins University School Of Medicine, The Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
EP1047449B1 (en) * 1997-10-28 2003-09-10 The University Of British Columbia Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
IL136114A0 (en) 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
CA2343313A1 (en) * 1998-09-14 2000-03-23 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
EP1146898A1 (en) 1999-01-22 2001-10-24 Matthew John During Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2001062907A1 (fr) 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Bibliotheque d'anticorps
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
CA2494008C (en) 2012-12-11
BR0312456A (pt) 2005-04-19
TW200403254A (en) 2004-03-01
US8071731B2 (en) 2011-12-06
AU2003255390A1 (en) 2004-02-25
NO333876B1 (no) 2013-10-07
PT1526868E (pt) 2014-01-07
PL375405A1 (en) 2005-11-28
CY1114919T1 (el) 2016-12-14
CN100542607C (zh) 2009-09-23
AR040778A1 (es) 2005-04-20
MXPA05001468A (es) 2005-06-06
DK1526868T3 (da) 2014-01-13
EP1526868A2 (en) 2005-05-04
HK1077206A1 (en) 2006-02-10
ES2440652T3 (es) 2014-01-29
KR20050049470A (ko) 2005-05-25
WO2004014953A2 (en) 2004-02-19
PL211014B1 (pl) 2012-03-30
IS7576A (is) 2004-11-30
CN1671417A (zh) 2005-09-21
US7612183B2 (en) 2009-11-03
JP2006512899A (ja) 2006-04-20
CA2494008A1 (en) 2004-02-19
NZ537123A (en) 2007-05-31
SI1526868T1 (sl) 2014-01-31
WO2004014953A3 (en) 2004-05-06
KR101078459B1 (ko) 2011-10-31
MY148409A (en) 2013-04-30
EP1526868B1 (en) 2013-10-23
US20060165681A1 (en) 2006-07-27
IL165478A (en) 2010-12-30
AU2003255390B2 (en) 2011-02-03
JP4528121B2 (ja) 2010-08-18
NO20045323L (no) 2005-02-10
US20090053214A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
TWI323265B (en) Antibodies
TWI329649B (en) Immunoglobulins
NL2002255C2 (nl) Antilichamen tegen myostatine.
JP5513888B2 (ja) グルカゴン受容体抗体に関する組成物および方法
JP2007530551A (ja) 抗ミオスタチン抗体
US20080014195A1 (en) Antagonists Of Myelin-Associated Glycoprotein And Their Use In The Treatment And/Or Prevention Of Neurological Diseases
JP2008539266A (ja) 下位運動ニューロン疾患の治療方法およびそれを含む組成物
JP4648895B2 (ja) 抗ミエリン関連糖タンパク質（ｍａｇ）抗体の治療での使用
RU2303461C9 (ru) Антитела против миелин-ассоциированного гликопротеина (mag)
HK1077206B (en) Anti-mag humanised antibodies and their uses for treating stroke
ZA200500337B (en) Anty-myelin associated glycoprotein (MAG) antibodies

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees